Santacruz Silver Mining CEO buys the fall pullback

Santacruz Silver Mining's CEO, Arturo Préstamo, discusses the company's growing silver production, including a new 500-tonne-per-day mill at San Lucas, a $120 million treasury, and plans to produce 2.5-3 million silver-equivalent ounces annually from Soracaya. He also shares his outlook for silver prices.

Tesla updated its Robotaxi app to show estimated arrival times and availability for Cybercab and Model Y, aiding rider decisions. Cybercab fleet grew to 573 in Texas, with plans to expand to Dallas. Elon Musk announced Cybertruck production will end by mid-2027 to prioritize Cybercab production. SpaceX targets November 13 for Starship Flight 15, aiming to catch the ship with the launch tower.

The U.S. Army awarded Pegasystems a software contract with a maximum value of $419 million. The agreement, lasting up to 10 years, covers subscriptions, cloud hosting, and professional services for authorized military organizations. Pegasystems was named the sole responsible source by the Army, citing its platform's unique features. The company announced the award on November 4.

AST SpaceMobile (ASTS) announced plans to build its own reusable rocket, Blacklift, for launching satellites starting in late 2028. Firefly Aerospace (FLY) will supply engines, valued at over $1.3B. ASTS shares rose 7.05%, while FLY surged 36.8%. The deal includes $800M upfront, including ASTS shares, and adds to ASTS's cash burn and dilution.

Novartis AG is halting development of pelacarsen, an experimental heart drug, after a key study showed no benefit in preventing heart attacks or cardiovascular deaths. The drug, which targets Lp(a), a cholesterol-carrying particle, failed to reduce heart attacks or strokes despite lowering Lp(a) levels. Novartis will continue one trial for a heart valve disease. The company has another experimental drug, DII235, in midstage testing.

Novartis NVS is halting development of Ionis IONS's heart drug pelacarsen after it failed a late-stage trial. The therapy did not meet its primary endpoint in the Lp(a)HORIZON trial for cardiovascular disease. Novartis will continue testing pelacarsen for calcific aortic valve stenosis. Amgen AMGN, Arrowhead ARWR, and Royalty Pharma RPRX also saw shares drop in September due to the setback.